
Pioneering next-generation serotonergic agonist therapies for durable mental health improvements
Cybin develops deuterated tryptamine analogs for depression and anxiety with improved pharmacokinetics. Its shorter-acting candidates share some mechanistic overlap with Gilgamesh's Bretisilocin but lack the same level of big-pharma acquisition validation to date.
Free